NCT06576037 2026-04-16
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
Phase 1 Recruiting
Clinical Trials
29 trialsNCT06233942 2026-04-15
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06265688 2026-03-25
First In Human Study of CX-2051 in Advanced Solid Tumors
CytomX Therapeutics
Phase 1 Recruiting
NCT05836324 2025-12-18
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Incyte Corporation
Phase 1 Recruiting
NCT06509906 2025-12-18
M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
EMD Serono
Phase 1 Terminated
NCT04185883 2025-10-22
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
Phase 1 Active not recruiting
NCT02020707 2024-07-26
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
Mayo Clinic
Phase 1 Completed
NCT06336707 2024-07-18
HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors
Hansoh BioMedical R&D Company
Phase 1 Recruiting
NCT00993044 2023-10-06
VIT-B
Children's Hospital Los Angeles
Phase 1 Completed
NCT02715531 2021-07-09
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT00786669 2021-02-10
VITAC
Children's Hospital Medical Center, Cincinnati
Phase 1 Completed
NCT00390156 2020-07-28
Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors
University of California, San Francisco
Phase 1 Completed
NCT02648711 2020-05-28
Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
Lumos Pharma
Phase 1 Terminated
NCT02665416 2020-04-07
Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT01332721 2018-12-05
Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
Tracon Pharmaceuticals Inc.
Phase 1 Completed
NCT00861419 2017-02-08
To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.
Amgen
Phase 1 Completed
NCT00416637 2016-07-07
Bevacizumab in Treating Patients With Advanced Solid Tumors
Duke University
Phase 1 Completed
NCT00888043 2015-03-11
CNTO95/Avastin
Duke University
Phase 1 Completed
NCT00781846 2015-02-13
Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00276575 2014-11-19
Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors
Duke University
Phase 1 Completed
NCT00586443 2014-11-19
BEP
Duke University
Phase 1 Completed
NCT00357318 2014-02-24
Bevacizumab and Sunitinib in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00085111 2013-06-05
Bevacizumab in Treating Young Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00550927 2013-05-15
Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer
Eli Lilly and Company
Phase 1 Completed
NCT00586092 2013-04-08
A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors
Duke University
Phase 1 Completed
NCT00049088 2013-01-24
Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01055795 2012-12-24
BEL
Duke University
Phase 1 Completed
NCT00005061 2012-07-18
Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Solid Tumors
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Completed
NCT00556088 2010-12-30
LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Completed